Clinical Trials Logo
  1. Home
  2. PD-1 Antibody
  3. NCT05461235

Anti-PD-1 Antibody Combined With Autologous DC and NK Cells in the Treatment of Digestive Carcinoma

PD-1 Antibody Clinical Trial

Official title:
A Prospective, Open, Single-arm Phase II Clinical Study to Evaluate the Efficacy and Safety of Anti-PD-1 Antibody Combined With Autologous DC and NK Cells in the Treatment of Digestive Carcinoma.

Clinical Trial Summary

This is a prospective, open, single-arm Phase II clinical study to evaluate the efficacy and safety of anti-PD-1 antibody combined with autologous DC and NK cells in the treatment of digestive carcinoma.

Clinical Trial Description

This is a prospective, open, single-arm Phase II clinical study to evaluate the efficacy and safety of anti-PD-1 antibody combined with autologous DC and NK cells in the treatment of digestive carcinoma. This project aims to enhance the anti-tumour activity of DC/NK cells in combination with anti-PD-1 antibodies, and ultimately activate the patient's own immune function to improve the quality of life and survival time of tumour patients, and provide objective evidence for the widespread use of targeted immune cell therapy in the clinical setting. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT05461235
Study type Interventional
Source China Medical University, China
Contact Yunpeng Liu, PhD
Phone 86-24-83282312
Email cmu_trial@163.com
Status Not yet recruiting
Phase Phase 2
Start date July 15, 2022
Completion date December 1, 2025
View Details
See also
  Status Clinical Trial Phase
Completed NCT04507217 - Tislelizumab Combined With Pemetrexed/ Carboplatin in Patients With Brain Metastases of Non-squamous NSCLC Phase 2
Not yet recruiting NCT04108013 - A Study of SHR-1210 in Combination With Carboplatin+Paclitaxel-albumin in Subjects With Resectable NSCLC Phase 2
Active, not recruiting NCT03668496 - A Study of SHR-1210 in Combination With Carboplatin + Paclitaxel in Subjects With Squamous NSCLC Phase 3
Not yet recruiting NCT04834674 - DEB-TACE Combined With Apatinib and PD-1 for the Treatment of Intrahepatic Cholangiocarcinoma Phase 2
Not yet recruiting NCT04944511 - PD-1 Antibody Improve Mixed Chimerism N/A
Not yet recruiting NCT03777124 - Phase II Study of SHR-1210(Anti-PD-1 Antibody) Combination With Apatinib Versus Pemetrexed and Carboplatin in Subjects With KRAS Mutant Stage IV Non-squamous Non-small Cell Lung Cancer Phase 2
Active, not recruiting NCT05156788 - Tislelizumab（Anti PD-1), Lenvatinib and GEMOX Transformation in the Treatment of Potentially Resectable, Locally Advanced Biliary Tract Cancer Phase 2
Recruiting NCT02873390 - PD-1 Antibody Expressing CAR-T Cells for EGFR Family Member Positive Advanced Solid Tumor Phase 1/Phase 2
Recruiting NCT02862028 - PD-1 Antibody Expressing CAR-T Cells for EGFR Family Member Positive Advanced Solid Tumor (Lung, Liver and Stomach) Phase 1/Phase 2
Recruiting NCT05554276 - Neoadjuvant Chemotherapy Combined With PD-1 + Radical Radiotherapy in Locally Advanced Cervical Cancer Phase 2
Not yet recruiting NCT05775705 - L-DEP Regimen Combined With PD-1 Antibody as Induction Therapy for Epstein-Barr Virus-positive LA-HLH Phase 3